Piramal Pharma Limited Boosts U.S. Presence with $90 Million Investment in Two Key Facilities

Piramal Pharma Limited Expands U.S. Operations with Significant Investment

Piramal Pharma Limited, a prominent global player in pharmaceuticals and wellness, is making waves with its latest announcement of a $90 million investment dedicated to expanding two key facilities in the United States. This strategic decision aligns with the objectives outlined during the 2025 SelectUSA Investment Summit, emphasizing the company’s commitment to enhancing its capabilities while meeting increasing customer demand.

Expansion Details

The planned expansions are set for the company’s facilities located in Lexington, Kentucky, and Riverview, Michigan. These two sites are poised to play crucial roles in Piramal’s efforts to bolster its manufacturing prowess within the U.S. market, particularly in light of a growing trend toward onshoring drug supply.

In Lexington, the focus will be on sterile injectables. The expansion will encompass the addition of 24,000 square feet of manufacturing space, complemented by a new laboratory which will facilitate significant commercial-scale production of injectable drug products. This includes the installation of a new filling line, two large-scale lyophilizers, and specialized equipment designed for efficient drug manufacturing. This expansion is expected to be operational by late 2027.

Meanwhile, in Riverview, Michigan, the facility will enhance its already well-established reputation for the development and production of active pharmaceutical ingredients (APIs), with specific focus on high potency APIs (HPAPIs). The new suite dedicated to payload-linkers, which are essential for creating bioconjugate drugs such as antibody-drug conjugates (ADCs), is set to commence operations by the end of 2025.

The Impact of the Expansions

The implications of these expansions are significant. They are anticipated to create new synergies across the company’s ADC projects, enabling faster project timelines from initiation to Good Manufacturing Practice (GMP) product completion. With the new ADCelerate program, Piramal Pharma aims to bring high-quality drug products to market in just 12 months, a remarkable achievement that underscores the company’s commitment to rapid and efficient drug development.

Peter DeYoung, CEO of Piramal Global Pharma, shared insights on the company’s ambitious plans, stating, “Since our inception, Piramal Pharma Ltd has invested $570 million in its U.S. drug development and manufacturing capabilities. Our investments will not only expand our footprint but also reinforce our position as a trusted partner for biologic manufacturers.” Currently, approximately 750 employees work at the company’s U.S. locations, and the expansions are expected to provide additional job opportunities in the region.

Piramal Pharma is dedicated to enhancing patient outcomes by reducing the burden of disease through innovative drug solutions. The strategic development of commercial-scale support in both sterile injectables and bioconjugates is crucial for meeting the increasing demands of the healthcare market.

Conclusion

These significant infrastructure investments mark a defining moment in Piramal Pharma’s ongoing expansion strategy and commitment to the U.S. market. As the company continues to scale operations, it reinforces its mission to deliver innovative and effective healthcare solutions.

For more information on Piramal Pharma Limited and its various health care products and services, visit their official website.